Disease overview Acute myeloid leukemia (AML) is a frequently fatal bone marrow stem cell
cancer characterized by unbridled proliferation of malignant marrow stem cells with …

Simple Summary FLT3 mutation is commonly present in newly diagnosed patients with
acute myeloid leukemia, and confers high relapse risk. Targeted therapies with FLT3 …

Measurable residual disease (MRD) assessment in acute myeloid leukemia (AML) has an
established role in disease prognostication, particularly in guiding decisions for …

Acute myeloid leukaemia (AML) is a heterogeneous disease with one of the worst survival
rates of all cancers. The bone marrow microenvironment is increasingly being recognised as …

Venetoclax is a potent inhibitor that specifically targets B-cell lymphoma-2 (BCL-2), which
has been demonstrated to be effective in preclinical studies utilizing acute myeloid leukemia …

Simple Summary The DEAD-box RNA helicase 41, DDX41, is one of the most frequently
identified mutations in myeloid neoplasms with germline predispositions, which represents …

Following the success of immunotherapies such as chimeric antigen receptor transgenic T-
cell (CAR-T) therapy, bispecific T-cell engager therapy, and immune checkpoint inhibitors in …

Simple Summary In patients with acute myeloid leukemia (AML), genetic mutations can
cause cells to evade regulated cell death (RCD), resulting in excessive cell proliferation. The …

Relapsed and/or refractory (R/R) acute myeloid leukemia (AML) is hallmarked by dramatic
prognosis. Treatment remains challenging, with allogeneic hematopoietic stem cell …

Objectives To compare the efficacy of venetoclax‐azacitidine (VEN–AZA) with AZA in the
real‐life for patients with first relapsed or refractory acute myeloid leukaemia (R/R AML) …